Royalty Report: Drugs, Bacterial Infection, Antibiotic – Collection: 266746

Licensor grants the nonexclusive license, under the Licensor Technology, to practice and use the Licensor Technology and the Licensed Products anywhere in the world for the sole purpose of engaging in those research and development activities that Licensee is expressly required or permitted to perform pursuant to this Agreement.

Licensor grants a nonexclusive license, under the Licensor Technology, to make, have made, manufacture and have manufactured anywhere in the world Licensed Products for sale in the Territory.

For the Trademark License,  Licensor grants an exclusive license under its entire right, title and interest in and to the Licensor Marks to use and display the Licensor Marks in connection with the Commercialization of Licensed Products within the Territory.

Daptomycin shall mean the molecule identified as the daptomycin molecule and all acids, salts and esters of such daptomycin molecule.

Daptomycin IV Product shall mean any pharmaceutical composition containing Daptomycin in all current and future formulations, but only if such pharmaceutical composition is formulated for delivery via Injection.  

Additional Daptomycin Product shall mean any pharmaceutical composition containing Daptomycin other than a Daptomycin N Product.

The mark is Cidecin or Cubicen. CUBICIN® daptomycin for injection, an intravenous, or I.V., antibiotic

Daptomycin is an antibiotic used to treat bacterial infections of the skin and underlying tissues.  Daptomycin is a lipopeptide antibiotic used in the treatment of systemic and life-threatening infections caused by Gram-positive organisms.

Licensor grants a non-exelusive license to use Licensor Know-How solely for the purposes of
—  making and having made Licensed Products on a worldwide basis for the use, sale, offering for sale and importation of Licensed Products in the Licensee Territory;
—  using, selling, offering for sale and importing Licensed Products in the Licensee Territory; and
—  developing Licensed Products on a worldwide basis for the use, sale, offering for sale and importation of Licensed Products in the Licensee Territory.

Licensee shall have the exclusive right to market and commercialize, including, without limitation, by conducting pre-marketing, advertising and promotion activities, and sponsoring medical education events, exhibits and symposia Licensed Products in all countries of the Licensee Territory during the Term.

Licensor grants an exclusive license under its entire right, title and interest in and to the Licensor Marks to use and display the Licensor Marks in connection with the Commercialization of Licensed Products within the Licensee Territory.

The marks include ICIDECIN.

Daptomycin is a lipopeptide antibiotic used in the treatment of systemic and life-threatening infections caused by Gram-positive organisms.

Licensees Product means either a Licensor Derivative Product which is a product for the making, using, selling, offering for sale, or import of which would, but for the licenses granted herein, infringe a valid claim of a Research Patent or that includes a Licensor Derivative; or Licensee Derivative Product which is a product containing a Licensee Derivative.

Licensor Derivative means a compound(s) prepared by Licensor pursuant to the Research Program and that is either a derivative of daptomycin created utilizing synthesis or biocatalysis technology developed or practiced by Licensor, or a derivative of any such derivative created utilizing synthesis or biocatalysis technology developed or practiced by Licensor, and/or compound(s) prepared by Licensee or its Affiliates or Sublicensees that are simple esters or salts of compounds.

Biocatalytic process means biocatalytic procedure or biocatalysis used by Licensor to prepare derivatives of daptomycin and, without limitation, any process or procedure using organisms, catalysts, whether whole cell or isolated enzyme-based, strains, vectors, proprietary catalyst  preparation procedures, aqueous buffers or organic solvents, modifiers and enzyme cofactors.

Licensor will use its proprietary combinatorial biocatalysis technology to create derivatives of lipopeptides, a novel class of anti-infectives.  And Licensee is currently developing Cidecin® (daptomycin for injection)–the first investigational antibiotic derived from this new class.

The Parties now terminate that License Agreement in order that they may enter into this Assignment and License Agreement whereby Licensor will obtain expanded rights.

With this agreement, Licensor shall assign, transfer, convey and deliver to Licensee all rights to Assigned Patents in a separate assignments for each of such Assigned Patents.

Licensor grants the worldwide, exclusive licenses
—  Under the Patents, to develop, manufacture, formulate, have manufactured, import, use, distribute for sale, market and sell Compound in the Field; and
—  To use the Know· How for the development, manufacture, formulation, use, distribution for sale, marketing, and sale of Compound consistent with the terms of this Agreement.

Daptomycin injection is used to treat certain blood infections or serious skin infections caused by bacteria in adults and children 1 year of age and older. Daptomycin injection is in a class of medications called cyclic lipopeptide antibiotics. It works by killing bacteria.

For the research licenses, Licensor grants during the Research Term a worldwide, exclusive, with reserved rights to Licensor, a license, under the Licensor Know-how and Patents as necessary for Licensee to conduct its obligations and tasks under the Research Plan.

For the commercialization license, Licensor grants during the Term of this Agreement a worldwide, exclusive license under the Licensors Know-how and Patents to use, make, have made, market, distribute, promote, offer for sale, sell, export and import Product, including the right to grant sublicenses to Affiliates and Sublicensees.

The oxazolidinone class of antibiotics is a relatively recent addition to the antimicrobial world and have been found to be especially useful in treating infections caused by Gram-positive bacteria.

The patents are for Method For Solid Phase Synthesis of Alcohol Derivatives and Resulting Compositions;  and Oxazolidinone Combinatorial Libraries, Compositions and Methods of Preparation.
This application discloses methods for the solid phase synthesis of oxazolidinones; oxazolidinone combinatorial libraries and methods for their synthesis; pharmaceutical compositions comprising bioactive oxazolidinone compounds, including those adapted for oral, topical or parenteral use for the treatment of bacterial infections; and methods of screening combinatorial libraries to detect compounds with activity for treatment of disease states such as inflammation, infection, hypertension, CNS disorders and cardiovascular disorders.

TITLE OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION
This application discloses combinatorial libraries comprising oxazolidinones; methods of preparation of the libraries; biologically active oxazolidinone compositions including compositions for use for the treatment of bacterial infections; and methods of screening combinatorial libraries to detect bioactive compounds useful for treatment of disease states such as inflammation, infection, hypertension, central nervous system disorders and cardiovascular disorders.

TITLE OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION
Biologically active oxazolidinones, libraries and pharmaceutical compositions, and methods of preparation are disclosed, wherein the biologically active oxazolidinones may be used in pharmaceutical applications including use as sedatives, anticonvulsants, muscle relaxants, anti-Parkinson agents, analgesics, antiinflammatories, local anesthetics, muscle contractants, antibiotic, antiviral, antiretroviral, antimalarials, diuretics, lipid regulating agents, antiandrogenic agents, antiparasitics, neoplastics, antineoplastics and chemotherapy agents, as well as for treatment of cardiovascular diseases, central nervous system diseases, cancer, metabolic disorders, infections and dermatological diseases as well as other biological disorders and infections.

University grants to Licensee the right to enter into sublicensing agreements.

This agreement also includes a non-exclusive grant back to University from Licensee.

First Licensed Product means the first federally approved Individual Licensed Product to be subjected to a governmental safety and efficacy approval process prior to market introduction, and which is sold in any country of the Territory.